| Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis Nature 476 (7359), 214-219, 2011 | 3030 | 2011 |
| Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis International IBD Genetics Consortium (IIBDGC), C Agliardi, L Alfredsson, ... Nature genetics 45 (11), 1353-1360, 2013 | 1361 | 2013 |
| Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients TL Sørensen, M Tani, J Jensen, V Pierce, C Lucchinetti, VA Folcik, S Qin, ... The Journal of clinical investigation 103 (6), 807-815, 1999 | 1236 | 1999 |
| Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility International Multiple Sclerosis Genetics Consortium*†, ANZgene, ... Science 365 (6460), eaav7188, 2019 | 981 | 2019 |
| Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement MS Freedman, EJ Thompson, F Deisenhammer, G Giovannoni, ... Archives of neurology 62 (6), 865-870, 2005 | 765 | 2005 |
| Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis C Bridel, WN Van Wieringen, H Zetterberg, BM Tijms, CE Teunissen, ... JAMA neurology 76 (9), 1035-1048, 2019 | 613 | 2019 |
| Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force F Deisenhammer, A Bartos, R Egg, NE Gilhus, G Giovannoni, S Rauer, ... European journal of neurology 13 (9), 913-922, 2006 | 412 | 2006 |
| Clinical relevance of brain volume measures in multiple sclerosis N De Stefano, L Airas, N Grigoriadis, HP Mattle, J O’Riordan, ... CNS drugs 28, 147-156, 2014 | 384 | 2014 |
| Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open … R Kapoor, PR Ho, N Campbell, I Chang, A Deykin, F Forrestal, N Lucas, ... The Lancet Neurology 17 (5), 405-415, 2018 | 347 | 2018 |
| Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course M Khademi, I Kockum, ML Andersson, E Iacobaeus, L Brundin, ... Multiple Sclerosis Journal 17 (3), 335-343, 2011 | 302 | 2011 |
| CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis C Trebst, TL Sørensen, P Kivisäkk, MK Cathcart, J Hesselgesser, R Horuk, ... The American journal of pathology 159 (5), 1701-1710, 2001 | 300 | 2001 |
| Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system TL Sørensen, C Trebst, P Kivisäkk, KL Klaege, A Majmudar, R Ravid, ... Journal of neuroimmunology 127 (1-2), 59-68, 2002 | 293 | 2002 |
| Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS F Sellebjerg, L Bornsen, M Khademi, M Krakauer, T Olsson, ... Neurology 73 (23), 2003-2010, 2009 | 260 | 2009 |
| T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis CJ Hedegaard, M Krakauer, K Bendtzen, H Lund, F Sellebjerg, ... Immunology 125 (2), 161-169, 2008 | 242 | 2008 |
| CCR5 Δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis F Sellebjerg, HO Madsen, CV Jensen, J Jensen, P Garred Journal of Neuroimmunology 102 (1), 98-106, 2000 | 212 | 2000 |
| Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17-and activated B-cells and correlates with progression. L Börnsen, R Ratzer, F Piehl, M Khademi, T Olsson, PS Sørensen, ... PloS one 8 (3), e57820-e57820, 2013 | 201 | 2013 |
| EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses F Sellebjerg, D Barnes, G Filippini, R Midgard, X Montalban, ... European journal of neurology 12 (12), 939-946, 2005 | 201 | 2005 |
| Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS F Sellebjerg, JL Frederiksen, PM Nielsen, J Olesen Neurology 51 (2), 529-534, 1998 | 201 | 1998 |
| Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17-and activated B-cells and correlates with progression JR Christensen, L Börnsen, R Ratzer, F Piehl, M Khademi, T Olsson, ... PloS one 8 (3), e57820, 2013 | 197 | 2013 |
| Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice JCC de Sa, L Airas, E Bartholome, N Grigoriadis, H Mattle, ... Therapeutic advances in neurological disorders 4 (3), 139-168, 2011 | 190 | 2011 |
Professor Torben Lykke SørensenZealand University Hospital & University of Copenhagen, DenmarkVerificeret mail på regionsjaelland.dk
